quetiapine + olanzapine + risperidone
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psychotic Disorders
Conditions
Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Trial Timeline
Aug 1, 2002 → Aug 1, 2006
NCT ID
NCT00222495About quetiapine + olanzapine + risperidone
quetiapine + olanzapine + risperidone is a pre-clinical stage product being developed by AstraZeneca for Psychotic Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00222495. Target conditions include Psychotic Disorders, Schizophrenia, Schizophreniform Disorders.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00222495 | Pre-clinical | Completed |
Competing Products
14 competing products in Psychotic Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine, Amantadine + Olanzapine and placebo | Eli Lilly | Phase 1 | 33 |
| risperidone IR and LAI formulation | Johnson & Johnson | Phase 1 | 33 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| Asenapine 5-20 mg daily + Placebo 1-4 tablets daily | Merck | Approved | 85 |
| Ziprasidone HCL (oral) | Pfizer | Approved | 84 |
| Aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Risperidone/Quetiapine | Bristol Myers Squibb | Pre-clinical | 22 |
| mifepristone + placebo | Corcept Therapeutics | Phase 3 | 72 |
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Miricorilant + Fluvoxamine | Corcept Therapeutics | Phase 1 | 28 |
| Miricorilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Olanzapine + CORT118335 + Placebo | Corcept Therapeutics | Phase 1 | 28 |